Evidence map›Paper›PMID 36232724›Full record

ArticleInternational journal of molecular sciences2022

Functional Plasmon-Activated Water Increases

Chun-Chao Chang, Chih-Yi Liu, I-Chia Su, Yuarn-Jang Lee, Hsing-Jung Yeh, Wen-Chao Chen, Chih-Jui Yu, Wei-Yu Kao, Yu-Chuan Liu, Chi-Jung Huang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. The metabolite ILA ofFrontiers in microbiology · 2025
    Article
  7. Review
  8. Virulence · 2024
    Review
  9. CombinedPharmaceuticals (Basel, Switzerland) · 2023
    Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Chun-Chao ChangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.ORCID 0000-0002-3396-1559
Chih-Yi LiuDepartment of Pathology, Sijhih Cathay General Hospital, New Taipei 221, Taiwan.
I-Chia SuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.
Yuarn-Jang LeeDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.
Hsing-Jung YehDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.ORCID 0000-0003-3415-836X
Wen-Chao ChenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.ORCID 0000-0001-5543-1690
Chih-Jui YuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.
Wei-Yu KaoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, Taiwan.ORCID 0000-0002-5506-4293
Yu-Chuan LiuDepartment of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0003-2111-8991
Chi-Jung HuangDepartment of Medical Research, Cathay General Hospital, Taipei 106, Taiwan.ORCID 0000-0001-8382-1303
Taipei Medical University Hospital · TWCathay General Hospital · TWFu Jen Catholic University · TWWan Fang Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is associated with dysbiosis and intestinal barrier dysfunction, as indicated by epithelial hyperpermeability and high levels of mucosal-associated bacteria. Changes in gut microbiota may be correlated with IBD pathogenesis. Additionally, microbe-based treatments could mitigate clinical IBD symptoms. Plasmon-activated water (PAW) is known to have an anti-inflammatory potential. In this work, we studied the association between the anti-inflammatory ability of PAW and intestinal microbes, thereby improving IBD treatment. We examined the PAW-induced changes in the colonic immune activity and microbiota of mice by immunohistochemistry and next generation sequencing, determined whether drinking PAW can mitigate IBD induced by 2,4,6-trinitrobenzene sulfonic acid (TNBS) and dysbiosis through mice animal models. The effects of specific probiotic species on mice with TNBS-induced IBD were also investigated. Experimental results indicated that PAW could change the local inflammation in the intestinal microenvironment. Moreover, the abundance of

Indexed as

Gastrointestinal MicrobiomeInflammatory Bowel DiseasesAkkermansiaAnimalsAnti-Inflammatory AgentsChronic DiseaseDysbiosisMiceSulfonic AcidsVerrucomicrobiaWaterAnti-Inflammatory AgentsSulfonic AcidsWaterAkkermansia muciniphilagut microbiotainflammatory bowel diseasemicrobial biomarkerplasmon-activated water

Identifiers

PMID36232724
PMCPMC9570201
OpenAlexW4297540599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.